Prostatype Genomics offers prostate cancer patients a decision support for the most optimal treatment option! We developed a test system called 'Prostatype® Test System'. The system is based on a gene expression test, which measures the expression of three carefully selected embryonic stem cell genes in prostate cancer core needle biopsies. In conjunction with currently used clinical parameters, the PrTS predicts overall survival in relation to treatment. The Prostatype® Test System helps to choose the optimal treatment strategy for each patient. This secures quality of life for patients with a low risk tumor without jeopardizing safety for patients with aggressive tumors.